Diamyd Medical AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Diamyd Medical AB
Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.
China Turns To New Vaccines As It Eases 'COVID Zero' Restrictions
In a significant policy shift and following recent public unrest, China now appears to be moving away from its strict "COVID Zero" restrictions to salvage a floundering economy hard hit by repeated lockdowns, as part of which it is looking to accelerate the approval of new vaccines and increase vaccination rates in the elderly.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong
Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.
- Site Specific
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Diamyd Therapeutics AB
- Diamyd Diagnostics AB
- Diamyd, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.